These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 35488163)
1. Emicizumab for All Pediatric Patients with Severe Hemophilia A. Wieland I Hamostaseologie; 2022 Apr; 42(2):104-115. PubMed ID: 35488163 [TBL] [Abstract][Full Text] [Related]
2. Emicizumab for hemophilia A without inhibitors. Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012 [No Abstract] [Full Text] [Related]
3. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595 [TBL] [Abstract][Full Text] [Related]
4. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A. Le Quellec S Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331 [TBL] [Abstract][Full Text] [Related]
5. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050 [No Abstract] [Full Text] [Related]
6. Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review. Hassan E; Motwani J Pediatr Hematol Oncol; 2022 Aug; 39(5):418-426. PubMed ID: 35170384 [TBL] [Abstract][Full Text] [Related]
7. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809 [TBL] [Abstract][Full Text] [Related]
8. Emicizumab for the prevention of bleeds in hemophilia A. Mahlangu J Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297 [No Abstract] [Full Text] [Related]
9. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146 [TBL] [Abstract][Full Text] [Related]
10. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients. Patil R; Shanmukhaiah C; Gogtay NJ; Pandey P; Patil K; Jijina F; Madkaikar M J Thromb Haemost; 2024 Apr; 22(4):1024-1030. PubMed ID: 38160726 [TBL] [Abstract][Full Text] [Related]
11. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586 [TBL] [Abstract][Full Text] [Related]
12. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Wang CP; Young G; Thornburg CD Expert Opin Drug Saf; 2021 Apr; 20(4):387-396. PubMed ID: 33612049 [TBL] [Abstract][Full Text] [Related]
13. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389 [TBL] [Abstract][Full Text] [Related]
14. Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single-center retrospective study. Cohen CT; Diaz R Pediatr Blood Cancer; 2021 Nov; 68(11):e29325. PubMed ID: 34490988 [TBL] [Abstract][Full Text] [Related]
15. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557 [TBL] [Abstract][Full Text] [Related]
18. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the safety of emicizumab in patients with hemophilia A. Langer AL; Etra A; Aledort L Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521 [TBL] [Abstract][Full Text] [Related]
20. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Ebbert PT; Xavier F; Seaman CD; Ragni MV Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]